Trial Profile
A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Zabinostat (Primary)
- Indications Carcinoma; Colorectal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms CAROSELL
- Sponsors Celleron Therapeutics; IngenOx Therapeutics
- 05 Jan 2023 According to a Celleron Therapeutics media release, Celleron Therapeutics has merged with the Argonaut Therapeutics to form IngenOx Therapeutics (www.ingenox.com).
- 29 Jun 2022 According to a Celleron Therapeutics media release, all ongoing subjects have completed study treatment.
- 29 Jun 2022 3-year survival data published in the Celleron Therapeutics Media Release.